Company intelligence / Profile preview

Aomo Pharma Inc.

Ownership: Private
Development stage: Phase 3

Overview

Aomo Pharma has a pipeline of over ten first-in-class drug candidates targeting anesthesia, cardiovascular, eye, neurodegenerative diseases, and cancers. Its lead candidate adamgammadex has completed two pivotal Phase III trials in China with an NDA accepted by the NMPA in September 2024. End-of-phase II meeting with the FDA was held in September 2022; multi-regional clinical trials are planned for the US, Europe, and Japan

Therapeutic areas: OncologyOtherCardiovascularOphthalmologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

Aom-0304

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aomo Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aomo Pharma Inc..

Explore the full profile